

June 3, 2026 03:36 AM GMT

Semiconductors | North America

Raising estimates/PTs for memory stocks as demand continues to outpace supply

WHAT'S CHANGED		
Micron Technology Inc. (MU.O)	From	To
Price Target	\$520.00	\$1,050.00
SanDisk Corporation. (SNDK.O)		
Price Target	\$1,100.00	\$1,750.00

Memory stocks were strong in 2025 and have continued to pace the market again in 2026, but we don't think the run of strong performance is over.

Key Takeaways

- DRAM the principle bottleneck in the AI buildout, NAND still very tight, driving continued growth in FCF/EPS as long as AI spending persists
- Both MU and Sandisk still <10x PE leaves room for further multiple expansion, and we think numbers continue to move higher
- HBM renegotiations in late 2026, expanded capital returns next catalysts for MU
- Raising MU pt to \$1,050, SNDK PT to \$1,750

There's no quick fix to the memory shortage, as we highlighted in our global note out today and Taiwan takeaways earlier this week. (Chipflation – Navigating A Memory Crisis; Takeaways from our meetings in Taiwan). That's going to drive what could be 2-3 more years (or longer) of tight supply conditions in memory. The shortage is most acute in DRAM, but in NAND as well. The market is beginning to appreciate what that means for the longevity of the current earnings streams with Micron's cons PE expanding from 4x to 11x since the end of March. So what's next?

For Micron we see (1) DRAM now increasingly the principal bottleneck to the AI buildout and hyperscalers willingness to pay remains high; (2) supply growth is limited by cleanroom and EUV availability. We think that keeps conditions tight and numbers will continue to move higher (we raise our CY26/CY27 EPS estimates by 4%/48%, on higher pricing). We now model DRAM pricing up 40% in the MayQ, and 15% in Aug, that's below expectations for 20% or more that we heard from the supply chain during our trip - but we wouldn't assume all the business is responding to those quarterly adjustments.

We still believe that multiple expansion can be a bigger driver of returns from here as investors price in a longer duration to earnings power. That said our working assumption remains that we'll see some correction in pricing and margins into

MORGAN STANLEY & CO. LLC

Joseph Moore

Equity Analyst

Joseph.Moore@morganstanley.com

+1 212 761-7516

Mason Wayne

Research Associate

Mason.Wayne@morganstanley.com

+1 212 761-6012

Shane Brett

Equity Analyst

Shane.Brett@morganstanley.com

+1 212 761-1022

Nicole Kozhukhov

Research Associate

Nicole.Kozhukhov@morganstanley.com

+1 212 761-1636

Ella Tulchinsky

Research Associate

Ella.Tulchinsky@morganstanley.com

+1 212 761-2222

2026 EXTEL

ALL-AMERICA

RESEARCH POLL

May 26 – June, 12 2026

VIEW OUR ANALYSTS >

SEMICONDUCTORS

North America

Industry View

Attractive

Morgan Stanley does and seeks to

companies covered in Morgan St

investors should be aware that th

interest that could affect the obje

Research. Investors should consi

Research as only a single factor i

decision.

For analyst certification and oth

refer to the Disclosure Section, I

report.

人在草木间


见手机扫码

QR CODE

CY2028, but that's not in evidence today. Meanwhile we expect buybacks to commence beginning in FY27 (we model \$50bn from FY27-28) - as MU has been largely restricted from buybacks due to chips act provisions.

Micron will be investing in significant footprint expansion as well, and for DRAM overall capital spending continues to be quite high relative to history, but its impact on bit growth will continue to be limited by increasing HBM volumes and its associated trade ratio. Bit supply growth will accelerate in 2027/2028 as new supply comes available but the pace is still gated by the timing of construction and facility ramps. We remain well above consensus on MU's FY27/28 capex, where we now model \$44bn/\$40bn vs \$37.6bn/\$36.9bn for consensus., that's a drag on our FCF estimates but our new modeling (presented at the end of the note) suggests the D&A impact is manageable. Further the incremental bit growth could be a source of revenue/eps upside should the market remain this tight - which we expect.

Exhibit 1: Micron Gross PPE by asset class, PPE to expand more by the end of FY27 than 1QFY20-2QFY26



Source: Company Data, Morgan Stanley

For Sandisk the situation is similar, hyperscalers continue to corner the market for higher performance NAND at a level that's meaningfully shifting the demand profile of the commodity - at the same time supply growth has been slow to adjust. At their investor day Sandisk JV partner Kioxia (covered by Kazuo Yoshikawa) just had their analyst day, and raised their expectations for long term bit growth only slightly, from 20% to 22%. That includes a much stronger contribution from AI inference, but with muted growth in PC/mobile markets. Given the only smaller increase in long term demand capex is expected to remain low at ¥470bn per year (For more see [MSR: Investor Day 2026](#)). That lower outlook for smartphone and PC demand is the primary driver of our relative preference for MU, where device de-specing is more difficult and the portion of bits doing into datacenter and AI markets is higher. That said Mobile/PC/Consumer weakness is not affecting the pricing environment for NAND and we are raising our Sandisk CY26/CY27 EPS estimates by 12%/24%, again on higher pricing.

We think both stocks can continue to outperform as the multiples remains reasonable on near term estimates (sub 10x PE on CY27 ests for both stocks), with

meaningful share buybacks likely to commence in 2027, specialty AI memory (HBM) contracts are negotiated higher, and Sandisk increases their penetration in the datacenter market.

There has been a lot of focus on new multi-year supply agreements in this context, our view is that LTA's should be considered as a symptom not a cause of a "higher for longer" outlook, and proof that hyperscalers intend to continue to expand their memory procurement in the coming years and see commitments as a necessary condition to secure supply. We think the market will reward the implied durability, but its supply and demand we are most focused on.

MU changes to est and PT: Our valuation methodology continues to be based on through cycle EPS, our prior PT of \$525 was based on ~25x through cycle EPS of \$21. As we now see earnings >\$17 per share each quarter of our forecast period we are raising our EPS estimate to \$35, a small premium to our new the FY21-FY28 average (\$34) as we still assume there will be peaks and valleys in earnings power over time. With 29.5x still in-line with the semis group.

Exhibit 2: Micron Changes to Estimates

	New		Old		Change (%)		Consensus	
	F3Q26E	CY2027E	F3Q26E	CY2027E	F3Q26E	CY2027E	F3Q26E	CY2027E
Revenue	\$13,643	\$200,395	\$13,643	\$144,196	0%	39%	\$34,270	\$179,945
Adj Gross Margin	82.2%	85.0%	81.6%	81.2%	1%	5%	79.8%	74.6%
Adj EPS	\$20.01	\$113.85	\$19.15	\$76.87	4%	48%	\$19.55	\$99.57

Source: Factset, Morgan Stanley Research

Sandisk changes to est and PT: Our valuation methodology continues to be based on through cycle EPS, our prior PT of \$1,100 was based on ~23x through cycle EPS of \$48. As we now see earnings surpassing ~\$200 per share next year we are raising our EPS estimate to \$62.50, a small premium to the FY21-FY28 average of \$56 given we are yet to see the impact of certain new opportunities in AI. We also assume a higher multiple, 28x vs 23x maintaining the slight discount to MU.

Exhibit 3: SNDK Changes to Estimates

	New		Old		Change (%)		Consensus (%)	
	CY2026E	CY2027E	CY2026E	CY2027E	CY2026E	CY2027E	CY2026E	CY2027E
Revenue	\$38,078	\$48,278	\$23,156	\$24,865	64%	94%	\$31,864	\$46,346
Adj Gross Margin	83.9%	86.0%	82.4%	83.3%	2%	3%	79%	84%
Adj EPS	\$161.07	\$208.11	\$143.41	\$167.23	12%	24%	\$ 123.55	\$ 190.74

Source: Factset, Morgan Stanley Research

Exhibit 4: Micron PPE and D&A build

Micron PP&E

Source: Company Filings, Morgan Stanley Estimates

	F1Q26A	F2Q26A	F3Q26E	F4Q26E	F1Q27E	F2Q27E	F3Q27E	F4Q27E	F1Q28E	F2Q28E	F3Q28E	F4Q28E
Gross PP&E												
Land	420	420	420	420	420	420	420	420	420	420	420	420
Buildings	22,860	23,305	25,413	27,534	29,526	31,874	34,758	37,636	39,437	41,233	42,712	44,188
Equipment	82,839	85,321	89,048	92,819	97,730	103,858	111,536	119,199	128,456	137,697	144,755	151,802
Construction in Progress	5,693	7,485	9,273	10,989	13,649	14,690	15,583	16,474	16,824	17,172	16,064	14,956
Software	1,678	1,764	1,911	2,059	2,236	2,439	2,682	2,925	3,176	3,426	3,610	3,793
Total	113,490	118,295	126,066	133,821	143,361	153,280	164,979	176,655	188,313	199,948	207,561	215,199
Accumulated Depreciation	(65,013)	(66,887)	(69,346)	(71,950)	(74,736)	(77,744)	(81,032)	(84,599)	(88,486)	(92,692)	(97,142)	(101,837)
Net PP&E	48,477	51,408	56,719	61,871	68,626	75,536	83,946	92,055	99,827	107,256	110,418	113,322
vs Balance Sheet	-	-	229	474	734	1,015	1,316	1,640	1,982	2,347	2,734	3,136
Capex Build		58,277						58,360			96,864	
Gross PP&E (BOP)	109,696	113,490	118,295	126,082	133,856	143,615	153,357	165,081	176,785	188,467	200,128	207,768
Capex Gross	\$5,399	\$6,367	\$8,800	\$8,800	\$10,800	\$10,800	\$12,000	\$12,000	\$12,000	\$12,000	\$12,000	\$8,000
Gov Incentives	-5978	-51,378	-5900	-5900	-5900	-5900	0	0	0	0	0	0
Other	(717)	(204)	(213)	(227)	(241)	(258)	(276)	(297)	(318)	(339)	(360)	(373)
Gross PP&E (EOP)	113,490	118,295	126,082	133,856	143,615	153,357	165,081	176,785	188,467	200,128	207,768	215,395
Other (Retirements, Acquisitions and Disposic	\$-717	\$-204	(213)	(227)	(241)	(258)	(276)	(297)	(318)	(339)	(360)	(373)
% of PP&E	-0.7%	-0.2%	-0.2%	-0.2%	-0.2%	-0.2%	-0.2%	-0.2%	-0.2%	-0.2%	-0.2%	-0.2%
Equipment Gross PP&E Additions	2,905	2,482	3,727	3,771	4,911	6,127	7,678	7,663	9,257	9,241	7,858	7,047
Y/Y % Growth	34%	21%	59%	47%	69%	147%	106%	103%	88%	51%	-8%	8%
% of Total	77%	52%	46.2%	46%	51%	51%	51%	51%	61%	61%	61%	61%
Y/Y Equipment Gross PP&E Additions	9,866	10,297	11,678	12,885	14,891	18,537	22,488	26,380	30,725	33,839	33,219	32,603
% of Total	71%	64%	59%	53%	50%	53%	58%	62%	69%	73%	78%	85%
Buildings Gross PP&E Additions	687	445	2,198	2,120	1,992	2,349	2,883	2,879	1,801	1,796	1,479	1,476
Y/Y % Growth	173%	-18%	135%	527%	190%	428%	38%	-1%	-24%	-46%	-49%	-49%
% of Total	18%	9%	25.0%	25%	20%	20%	20%	20%	10%	10%	10%	10%
Y/Y Buildings & Land Gross PP&E Additions	2,535	2,434	3,578	5,361	6,666	8,569	9,345	10,103	9,912	9,359	7,954	6,552
% of Total	18%	15%	18%	22%	22%	24%	24%	24%	22%	20%	19%	17%
Construction in Progress Gross PP&E Additions	175	1,792	2,312	2,311	2,850	2,849	3,223	3,221	3,220	3,219	2,137	2,136
Y/Y % Growth	-80%	1607%	353%	289%	1529%	69%	39%	-1%	13%	-1%	-34%	-34%
% of Total	5%	37%	27.0%	27%	27%	27%	27%	27%	27%	27%	27%	27%
Y/Y Construction in Progress Gross PP&E Ad	1,371	3,058	4,336	5,471	7,956	7,205	6,310	5,485	3,175	2,482	481	(1,519)
% of Total	10%	19%	22%	23%	26%	21%	16%	13%	7%	5%	1%	-4%
CIP Placed in Service (4Q Lag)												
Equipment	394	449	135	1,342	1,731	1,730	2,134	2,134	2,133	2,413	2,412	2,412
Buildings	108	123	37	422	544	544	671	671	671	758	758	758
Software	8	9	3	29	37	37	45	45	51	51	51	51
Land	-	-	-	-	-	-	-	-	-	-	-	-
Software Gross PP&E Additions	27	86	151	151	181	206	248	247	255	255	189	189
Y/Y % Growth	-78%	160%	28%	910%	569%	140%	64%	63%	41%	24%	-24%	-24%
% of Total	1%	2%	1.8%	1.8%	1.8%	1.8%	1.8%	1.8%	1.8%	1.8%	1.8%	1.8%
Y/Y Software Gross PP&E Additions	192	246	275	408	558	675	771	865	939	987	928	868
% of Total	1%	2%	1%	2%	2%	2%	2%	2%	2%	2%	2%	2%
Land Gross PP&E Additions	-	-	-	-	-	-	-	-	-	-	-	-
Y/Y % Growth	-100%	#DIV/0!	-100%	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
% of Total	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Y/Y Land Gross PP&E Additions	68	68	-	-	-	-	-	-	-	-	-	-
% of Total	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Total Gross PPE Additions	3,794	4,805	8,297	8,354	9,934	11,531	14,032	14,010	14,533	14,511	10,863	10,848
Check	-	-	-	(0)	1	2	4	4	(1)	(1)	(1)	(1)
Depreciation Build												
Existing Depreciation	\$2,212	\$2,286	\$2,316	\$2,316	\$2,316	\$2,316	\$2,316	\$2,316	\$2,316	\$2,316	\$2,316	\$2,316
Incremental D&A	\$63	\$74	\$143	\$288	\$469	\$693	\$972	\$1,251	\$1,571	\$1,890	\$2,134	\$2,378
Total D&A	\$2,275	\$2,360	\$2,459	\$2,604	\$2,785	\$3,009	\$3,288	\$3,567	\$3,887	\$4,206	\$4,450	\$4,694
vs Cash Flow Statement	-	-	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Avg Useful Life (ex CIP)	11.98	11.95	11.57	11.50	11.35	11.16	10.95	10.86	10.68	10.54	10.52	10.44
Elapsed Life (ex CIP)	7.24	7.21	7.08	7.26	7.36	7.42	7.46	7.62	7.68	7.80	8.03	8.20
Remaining Useful Life for existing D&A (ex CIP)	4.74	4.74	4.49	4.24	3.99	3.74	3.49	3.24	2.99	2.74	2.49	2.24
Accumulated D&A	(65,013)	(66,887)	(69,346)	(71,950)	(74,736)	(77,744)	(81,032)	(84,599)	(88,486)	(92,692)	(97,142)	(101,837)
Retirements	(717)	(204)	(213)	(227)	(241)	(258)	(276)	(297)	(318)	(339)	(360)	(373)
Incremental Equipment PPE	\$3,727	\$3,771	\$4,911	\$6,127	\$7,678	\$9,257	\$10,827	\$12,406	\$13,985	\$15,564	\$17,143	\$18,722
Useful Life	8	8	8	8	8	8	8	8	8	8	8	8
Equipment D&A Schedule												
F3Q26E			\$116	\$116	\$116	\$116	\$116	\$116	\$116	\$116	\$116	\$116
F4Q26E			\$118	\$118	\$118	\$118	\$118	\$118	\$118	\$118	\$118	\$118
F1Q27E				\$153	\$153	\$153	\$153	\$153	\$153	\$153	\$153	\$153
F2Q27E					\$191	\$191	\$191	\$191	\$191	\$191	\$191	\$191
F3Q27E						\$240	\$240	\$240	\$240	\$240	\$240	\$240
F4Q27E							\$239	\$239	\$239	\$239	\$239	\$239
F1Q28E								\$289	\$289	\$289	\$289	\$289
F2Q28E									\$289	\$289	\$289	\$289
F3Q28E										\$221	\$221	\$221
F4Q28E											\$220	\$220
Total			\$116	\$234	\$388	\$579	\$819	\$1,059	\$1,348	\$1,637	\$1,857	\$2,078
Incremental Land and Buildings PPE	\$2,108	\$2,120	\$1,992	\$2,349	\$2,883	\$2,879	\$1,801	\$1,796	\$1,796	\$1,479	\$1,476	\$1,476
Useful Life	30	30	30	30	30	30	30	30	30	30	30	30
Land and Buildings D&A Schedule												
F3Q26E			\$18	\$18	\$18	\$18	\$18	\$18	\$18	\$18	\$18	\$18
F4Q26E			\$18	\$18	\$18	\$18	\$18	\$18	\$18	\$18	\$18	\$18
F1Q27E				\$17	\$17	\$17	\$17	\$17	\$17	\$17	\$17	\$17
F2Q27E					\$20	\$20	\$20	\$20	\$20	\$20	\$20	\$20
F3Q27E						\$24	\$24	\$24	\$24	\$24	\$24	\$24
F4Q27E							\$24	\$24	\$24	\$24	\$24	\$24
F1Q28E								\$15	\$15	\$15	\$15	\$15
F2Q28E									\$15	\$15	\$15	\$15
F3Q28E										\$12	\$12	\$12
F4Q28E											\$12	\$12
Total			\$18	\$35	\$52	\$71	\$95	\$119	\$134	\$149	\$162	\$174
Incremental Software PPE	\$147	\$148	\$177	\$202	\$243	\$243	\$251	\$251	\$250	\$184	\$183	\$183
Useful Life	4	4	4	4	4	4	4	4	4	4	4	4
Software D&A Schedule												
F3Q26E			\$9	\$9	\$9	\$9	\$9	\$9	\$9	\$9	\$9	\$9
F4Q26E			\$9	\$9	\$9	\$9	\$9	\$9	\$9	\$9	\$9	\$9
F1Q27E				\$11	\$11	\$11	\$11	\$11	\$11	\$11	\$11	\$11
F2Q27E					\$13	\$13	\$13	\$13	\$13	\$13	\$13	\$13
F3Q27E						\$15	\$15	\$15	\$15	\$15	\$15	\$15
F4Q27E							\$15	\$15	\$15	\$15	\$15	\$15
F1Q28E								\$16	\$16	\$16	\$16	\$16
F2Q28E									\$16	\$16	\$16	\$16
F3Q28E										\$11	\$11	\$11
F4Q28E											\$11	\$11
Total			\$9	\$18	\$30	\$42	\$57	\$73	\$88	\$104	\$115	\$127

Source: Company Data, Morgan Stanley Research


Risk Reward – SanDisk Corporation. (SNDK.O)

NAND improving quickly on the back of accelerating cloud demand

PRICE TARGET \$1,750.00

We assume 28x through-cycle EPS of \$62.50 (vs. our estimate of FY21-FY29 average of \$56). As improving industry dynamics as well as eSSD demand lead to sustained levels of higher profitability, 28x is a slight discount to our through-cycle multiple target for MU (28.5x) as the lower AI exposure is offset by historically higher FCF conversion

Consensus Price Target Distribution



RISK REWARD CHART



BULL CASE \$2,635.00

31x through-cycle EPS of \$85

Our bull case of \$2,635 per share represents 31x a higher through-cycle EPS of \$85.00. Here future peak earnings look similar to the current environment, with AI demand supporting through cycle EPS about 40% of current cycle peak. As well as with more mild downturns, higher levels of profitability supporting a higher multiple.

BASE CASE \$1,750.00

28x through-cycle EPS of \$62.50

Improving industry dynamics as well as eSSD demand lead to higher levels of profitability than we have seen over the last few years, 28x is a discount to our through-cycle multiple target for MU (28.5x) as the lack of direct AI is offset by historically higher FCF conversion.

BEAR CASE \$1,100.00


25x through-cycle EPS of \$44

We think Sandisk can avoid much of the pain of the last downturn (\$13 per share loss), and with a better upcycle, with the multiple towards the average of the semiconductor group.

OVERWEIGHT THESIS

AI demand is in the process of transforming the NAND market, and driving peak cycle EPS to multiples of what we have seen in the past. With still minimal new investment in capacity and evolving AI demand drivers we see a long runway for upward revisions.

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

New Data Era: *Positive*
Secular Growth: *Positive*

View descriptions of Risk Rewards Themes [here](#)

Risk Reward – SanDisk Corporation. (SNDK.O)


KEY EARNINGS INPUTS

Drivers	2025	2026e	2027e	2028e
GAAP Revenue (\$, mm)	7,355	19,287	40,860	38,440
Non-GAAP Gross Margin (%)	30.3	68.9	84.1	82.4
Non-GAAP EPS (\$)	2.74	63.96	172.48	154.25
Inventory (\$, mm)	2,079	2,107	2,451	2,412
DOI	145.5	126.2	135.1	128.0

INVESTMENT DRIVERS

- Improved pricing and demand strength drive earnings growth
- Position in DC SSD market improves

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

5/5 BEST	24 Month Horizon	5/5 MOST	3 Month Horizon
-------------	---------------------	-------------	--------------------

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Quicker eSSD penetration in the datacenter
- Higher NAND content growth from edge AI applications
- Sandisk's investments in advanced memory technologies such as HBF (high Bandwidth Flash) pay dividends

RISKS TO DOWNSIDE

- NAND industry growth disappoints
- Capex growth returns as industry participants invest to gain share
- Sandisk loses market share as they fail to gain traction in datacenter
- China continues to gain share

OWNERSHIP POSITIONING

Inst. Owners, % Active	48.6%				
HF Sector Long/Short Ratio	2x				
HF Sector Net Exposure	25.3%				

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Jun 2027e

EPS (\$)	128.03	172.48	217.70
		171.23	
Sales / Revenue (\$, mm)	32,937	40,860	52,009
		42,102	
EBIT (\$, mm)	24,021	31,947	40,402
		32,112	

◆ Mean ◆ Morgan Stanley Estimates
Source: Refinitiv, Morgan Stanley Research

Risk Reward – Micron Technology Inc. (MU.O)


See multiple quarters of upward revisions, with AI driving a higher multiple

PRICE TARGET \$1,050.00


~29.5x through-cycle earnings of US \$35.00, a premium to history reflecting new opportunities in AI, in-line with broader semis.

Consensus Price Target Distribution

Source: Refinitiv, Morgan Stanley Research



RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)




Key: — Historical Stock Performance ● Current Stock Price ◆ Price Target

Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 2 Jun 2026. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology [here](#)

OVERWEIGHT THESIS

- DRAM fundamentals are in uncharted territory, and should continue to improve as datacenter/AI continue their upward trajectory
- Execution on AI is underappreciated, and we expect Micron to maintain HBM share in CY26 vs the competition. Supporting margins and driving a higher multiple than prior cycles
- Cycle longevity will be key, and S/D may stay tight for 2-3 more years

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

New Data Era: *Positive*
Secular Growth: *Positive*

View descriptions of Risk Rewards Themes [here](#)

BULL CASE \$1,650.00

33x through-cycle earnings of US\$50

Gross margin improvement continues, driven by scale, AI mix, and cost improvements in new products. Pricing pressure alleviates as demand sustainably moves above supply driven by HBM's wafer intensity, a product category where MU cements performance leadership on future products.

BASE CASE \$1,050.00

~29.5x through-cycle earnings of US\$35

Our through-cycle earnings estimate of US\$35.00 is a small premium to our new FY21-FY28 average (\$34) as we continue to assume peaks and valleys in earnings over time. Our 29.5x multiple reflects the market's enthusiasm for the AI opportunity, and at the midpoint of the semis group

BEAR CASE \$675.00

27x through-cycle earnings of US\$25.00

Memory begins to enter a downturn in early 2027. As the strength attributed to demand in the early part of the year ended up being inventory build at customers. Multiple compresses severely after an underwhelming peak

Risk Reward – Micron Technology Inc. (MU.O)


KEY EARNINGS INPUTS

Drivers	2025	2026e	2027e	2028e
GAAP Revenue (\$, mm)	37,378	113,029	193,866	174,254
Non Gaap Gross Margin (%)	40.9	78.3	85.1	80.0
Non-GAAP EPS (\$)	8.29	61.23	109.69	93.44
Inventory (\$, mm)	8,355	8,564	10,152	12,393
DOI	133.7	123.5	124.2	126.2

INVESTMENT DRIVERS

- Improved pricing and demand strength drive earnings growth

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies [here](#)

MS ALPHA MODELS

5/5 BEST	24 Month Horizon	4/5 MOST	3 Month Horizon
---------------------	-----------------------------	---------------------	----------------------------

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Customers continue to demonstrate an appetite to take on inventory around macroeconomic uncertainty
- Additional wafer intensity of HBM further improves overall supply and demand
- Micron's HBM share surpasses expectations

RISKS TO DOWNSIDE

- Pricing can turn quickly; a falter in end demand with inventories elevated could lead to a swift price reduction
- HBM demand falters and competition intensifies, pressuring pricing


OWNERSHIP POSITIONING

Inst. Owners, % Active	46.5%	
HF Sector Long/Short Ratio	2x	
HF Sector Net Exposure	25.3%	

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure - Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Oct 2026e



Source: Refinitiv, Morgan Stanley Research

Risk Reward Reference links

1. View explanation of Options Probabilities methodology - [Options_Probabilities_Exhibit_Link.pdf](#)
2. View descriptions of Risk Rewards Themes - [RR_Themes_Exhibit_Link.pdf](#)
3. View explanation of regional hierarchies - [GEG_Exhibit_Link.pdf](#)
4. View explanation of Theme/Exposure methodology - [ESG_Sustainable_Solutions_External_Link.pdf](#)
5. View explanation of HERS methodology - [ESG_HERS_External_Link.pdf](#)

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/eqr/disclosures/webapp/generalresearch, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Shane Brett; Nicole Kozhukhov; Joseph Moore; Ella Tulchinsky; Mason Wayne.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

As of April 30, 2026, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Advanced Micro Devices, Aeva Technologies Inc, Allegro Microsystems Inc, Ambarella Inc, Analog Devices Inc., Arm Holdings plc, Astera Labs Inc, Broadcom Inc., Cadence Design Systems Inc, Intel Corporation, IonQ Inc, Marvell Technology Group Ltd, Microchip Technology Inc., Micron Technology Inc., NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., Qualcomm Inc., SanDisk Corporation., Semtech Corp., Silicon Laboratories Inc., Skyworks Solutions Inc, Synopsys Inc., Texas Instruments, Wolfspeed, INC.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of Analog Devices Inc., Broadcom Inc., GlobalFoundries Inc, Intel Corporation, NXP Semiconductor NV, ON Semiconductor Corp., Semtech Corp.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Advanced Micro Devices, Aeva Technologies Inc, Allegro Microsystems Inc, Amkor Technology Inc, Analog Devices Inc., Broadcom Inc., Intel Corporation, IonQ Inc, Micron Technology Inc., NXP Semiconductor NV, ON Semiconductor Corp., Semtech Corp., Texas Instruments. In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Advanced Micro Devices, Aeva Technologies Inc, Allegro Microsystems Inc, Ambarella Inc, Amkor Technology Inc, Analog Devices Inc., Arm Holdings plc, Astera Labs Inc, Broadcom Inc., Cadence Design Systems Inc, GlobalFoundries Inc, Intel Corporation, IonQ Inc, Marvell Technology Group Ltd, Microchip Technology Inc., Micron Technology Inc., Navitas Semiconductor Corp, NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., Qualcomm Inc., SanDisk Corporation., Semtech Corp., Silicon Laboratories Inc., Skyworks Solutions Inc, Synopsys Inc., Texas Instruments, Wolfspeed, INC.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Advanced Micro Devices, Ambarella Inc, Amkor Technology Inc, Analog Devices Inc., Broadcom Inc., Cadence Design Systems Inc, GlobalFoundries Inc, Intel Corporation, Marvell Technology Group Ltd, Microchip Technology Inc., Micron Technology Inc., NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., Qualcomm Inc., Silicon Laboratories Inc., Synopsys Inc., Texas Instruments.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Advanced Micro Devices, Aeva Technologies Inc, Allegro Microsystems Inc, Ambarella Inc, Amkor Technology Inc, Analog Devices Inc., Arm Holdings plc, Astera Labs Inc, Broadcom Inc., Cadence Design Systems Inc, GlobalFoundries Inc, Intel Corporation, IonQ Inc, Marvell Technology Group Ltd, Microchip Technology Inc., Micron Technology Inc., Navitas Semiconductor Corp, NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., Qualcomm Inc., SanDisk Corporation., Semtech Corp., Silicon Laboratories Inc., Skyworks Solutions Inc, Synopsys Inc., Texas Instruments, Wolfspeed, INC.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Advanced Micro Devices, Ambarella Inc, Amkor Technology Inc, Analog Devices Inc., Broadcom Inc., Cadence Design Systems Inc, GlobalFoundries Inc, Intel Corporation, IonQ Inc, Marvell Technology Group Ltd, Microchip Technology Inc., Micron Technology Inc., NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., Qualcomm Inc., Semtech Corp., Silicon Laboratories Inc., Synopsys Inc., Texas Instruments, Wolfspeed, INC.

Morgan Stanley & Co. LLC makes a market in the securities of Aeva Technologies Inc, Ambarella Inc, Silicon Laboratories Inc.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of May 31, 2026)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm.

For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

Stock Rating Category	Coverage Universe		Investment Banking Clients (IBC)			Other Material Investment Services Clients (MISC)	
	Count	% of Total	Count	% of Total IBC	% of Rating Category	Count	% of Total Other MISC
Overweight/Buy	1542	42%	465	51%	30%	707	43%
Equal-weight/Hold	1571	43%	369	40%	23%	723	44%
Not-Rated/Hold	3	0%	0	0%	0%	1	0%
Underweight/Sell	551	15%	86	9%	16%	201	12%
Total	3,667		920			1632	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.


In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Stock Price, Price Target and Rating History (See Rating Definitions)

Micron Technology Inc. (MU.O) - As of 06/03/26 GMT in USD
Industry : Semiconductors



Stock Rating History: 6/1/21 : O/I; 8/12/21 : E/I; 7/21/22 : U/I; 12/7/23 : U/A; 5/20/24 : E/A; 10/6/25 : O/A


Price Target History: 3/1/21 : 105; 8/12/21 : 75; 12/20/21 : 77; 3/29/22 : 83; 6/21/22 : 56; 9/30/22 : 49; 12/21/22 : 46;
9/24/23 : 58.5; 11/27/23 : 71.5; 12/20/23 : 74.75; 3/18/24 : 78; 3/21/24 : 98; 5/20/24 : 130; 6/23/24 : 140; 9/15/24 : 100;
9/26/24 : 114; 12/19/24 : 98; 1/27/25 : 91; 3/21/25 : 112; 5/7/25 : 98; 6/26/25 : 135; 9/22/25 : 160; 10/6/25 : 220; 11/12/25 : 325;
11/23/25 : 338; 12/17/25 : 350; 2/10/26 : 450; 3/18/26 : 520

Source: Morgan Stanley Research Date Format : MM/DD/YY Price Target -- No Price Target Assigned (NA)
Stock Price (Not Covered by Current Analyst) — Stock Price (Covered by Current Analyst) —
Stock and Industry Ratings (abbreviations below) appear as ♦ Stock Rating/Industry View
Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NA)
Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Effective January 13, 2014, the stocks covered by Morgan Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage.

Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

SanDisk Corporation. (SNDK.O) - As of 06/03/26 GMT in USD
Industry : Semiconductors



Stock Rating History: 6/1/21 : E/I; 12/7/23 : E/A; 3/3/25 : O/A

Price Target History: 3/3/25 : 84; 5/7/25 : 70; 9/11/25 : 96; 11/2/25 : 230; 11/7/25 : 263; 11/23/25 : 273; 1/26/26 : 483;
1/29/26 : 690; 4/27/26 : 1100

Source: Morgan Stanley Research Date Format : MM/DD/YY Price Target -- No Price Target Assigned (NA)
Stock Price (Not Covered by Current Analyst) — Stock Price (Covered by Current Analyst) —
Stock and Industry Ratings (abbreviations below) appear as ♦ Stock Rating/Industry View
Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NA)
Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Effective January 13, 2014, the stocks covered by Morgan Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage.

Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding any material conflict of interest that can reasonably be expected to have influenced Morgan Stanley Smith Barney LLC's choice of a third-party research provider or the subject company of a third-party research report, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures. For Morgan Stanley specific disclosures, you may refer to <https://www.morganstanley.com/eqr/disclosures/webapp/generalresearch>.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

A member of Research who had or could have had access to the research prior to completion owns securities (or related derivatives) in the Micron Technology Inc., NVIDIA Corp.. This person is not a research analyst or a member of research analyst's household.

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (<http://www.morganstanley.com/terms.html>). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html). Please use the provided link to review the Terms and Conditions and Most Important Terms and Conditions for Morgan Stanley India Company Private Limited (https://www.morganstanley.com/assets/pdfs/about-us-global-offices/india/Terms_and_conditions.pdf) and the following link to review the audit report (https://ny.matrix.ms.com/eqr/research/webapp/researchdocs/MSICPL_Morgan_Stanley_Research_Audit_Report.pdf).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research. Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the

appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V which is regulated by Comision Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FC0118); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com. Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts; in Canada by Morgan Stanley Canada Limited; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products.

Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

INDUSTRY COVERAGE: Semiconductors

COMPANY (TICKER)	RATING (AS OF)	PRICE* (06/02/2026)
Joseph Moore		
Advanced Micro Devices (AMD.O)	E (06/09/2024)	\$521.54

Aeva Technologies Inc (AEVA.O)	E (07/19/2021)	\$27.76
Allegro Microsystems Inc (ALGM.O)	O (02/13/2026)	\$50.33
Ambarella Inc (AMBA.O)	O (03/29/2016)	\$78.38
Amkor Technology Inc (AMKR.O)	E (11/08/2023)	\$74.74
Analog Devices Inc. (ADI.O)	O (11/16/2023)	\$423.20
Astera Labs Inc (ALAB.O)	O (05/11/2025)	\$355.76
Broadcom Inc. (AVGO.O)	O (06/09/2024)	\$481.57
GlobalFoundries Inc (GFS.O)	E (10/28/2024)	\$84.60
Intel Corporation (INTC.O)	E (02/22/2023)	\$107.93
IonQ Inc (IONQ.N)	E (04/25/2023)	\$71.40
Marvell Technology Group Ltd (MRVL.O)	E (09/14/2015)	\$290.79
Microchip Technology Inc. (MCHP.O)	E (07/10/2024)	\$96.96
Micron Technology Inc. (MU.O)	O (10/06/2025)	\$1,064.10
Navitas Semiconductor Corp (NVT.S.O)	U (04/06/2025)	\$25.86
NVIDIA Corp. (NVDA.O)	O (03/16/2023)	\$222.82
NXP Semiconductor NV (NXPI.O)	O (02/11/2025)	\$323.62
ON Semiconductor Corp. (ON.O)	E (05/11/2025)	\$128.64
Qorvo Inc (QRVO.O)	E (10/28/2025)	\$102.74
Qualcomm Inc. (QCOM.O)	U (02/10/2026)	\$240.84
SanDisk Corporation. (SNDK.O)	O (03/03/2025)	\$1,716.36
Semtech Corp. (SMT.C.O)	E (04/06/2025)	\$166.63
Silicon Laboratories Inc. (SLAB.O)	E (01/19/2021)	\$218.75
Skyworks Solutions Inc (SWKS.O)	E (11/28/2018)	\$79.12
Texas Instruments (TXN.O)	U (04/13/2020)	\$308.12
Wolfspeed, INC (WOLF.N)	NR (04/06/2025)	\$61.06
Lee Simpson		
Arm Holdings plc (ARM.O)	E (04/07/2026)	\$402.71
Cadence Design Systems Inc (CDNS.O)	O (02/14/2024)	\$416.39
Synopsys Inc. (SNPS.O)	E (02/27/2026)	\$508.35

Stock Ratings are subject to change. Please see latest research for each company.

* Historical prices are not split adjusted.